Mucoxin (acetogenin) reduces proinflammatory cytokines in breast cancer

1Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Mucoxin is a potential compound used as an anticancer agent. Mucoxin induced apoptosis and inhibit proliferation in T47D breast cancer cells line. This study aims to determine the effect of mucoxin on proinflamatory cytokine in breast cancer. proinflamatory cytokine play important role in the development and metastasis of cancer cells. Breast cancer cell line MCF-7 were grouped into five groups referred to mucoxin doses assays, they are 0 ng/mL; 0.1 ng / mL; 0,5 ng/mL; 1 ng/mL; 5 ng/mL with three replication of each. Mucoxin was given for 48 hours. The levels of IL 6 and TNF-a assayed using ELISA methods. The results showed mucoxin decreases IL 6 levels in all treatment doses, but was not significant. Mucoxin also decreases TNF-a levels, with a significant reduction occurring at doses of 1 ng/mL and 5 ng/mL. It is suggested that mucoxin has potent to inhibit proinflammatory cytokines that play a role in the development and metastasis of breast cancer.

Author supplied keywords

Cite

CITATION STYLE

APA

Muhartono, Subeki, & Hanriko, R. (2019). Mucoxin (acetogenin) reduces proinflammatory cytokines in breast cancer. Biomedical and Pharmacology Journal, 12(1), 479–483. https://doi.org/10.13005/bpj/1664

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free